Literature DB >> 15380451

Heparin-binding EGF-like growth factor induces expression of lectin-like oxidized LDL receptor-1 in vascular smooth muscle cells.

Eri Mukai1, Noriaki Kume, Kazutaka Hayashida, Manabu Minami, Yuichiro Yamada, Yutaka Seino, Toru Kita.   

Abstract

Receptor-mediated endocytosis of oxidized LDL (Ox-LDL) has been implicated in lipid accumulation and vascular cell dysfunction. Lectin-like Ox-LDL receptor-1 (LOX-1) is highly inducible by proinflammatory cytokines, as well as angiotensin II and Ox-LDL in vitro. LOX-1 is expressed in macrophages and smooth muscle cells accumulated in the intima of advanced atherosclerotic plaques in vivo. Here we show that heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for vascular smooth muscle cells, induces LOX-1 expression in cultured bovine aortic smooth muscle cells. HB-EGF (1-100 ng/ml) induced LOX-1 expression, which was peaked between 8 and 16 h after HB-EGF stimulation. HB-EGF-induced expression of LOX-1 was suppressed by ZD1839, an inhibitor of EGF receptor phosphorylation. Both MEK and p38 mitogen-activated protein kinase (MAPK) inhibitors significantly blocked LOX-1 upregulation induced by HB-EGF. Phosphatidylinositol 3-kinase (PI3K) inhibitors also blocked HB-EGF-induced LOX-1 expression. HB-EGF induced phosphorylation of ERK, p38 MAPK and Akt, which were suppressed by ZD1839. Upregulated expression of LOX-1 was associated with enhanced uptake of DiI-labeled Ox-LDL in smooth muscle cells. Taken together, HB-EGF can also act as an inducer of LOX-1 expression and play an integral role in foam cell transformation, cellular dysfunction, and proliferation of smooth muscle cells in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380451     DOI: 10.1016/j.atherosclerosis.2004.03.028

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling.

Authors:  Hua Zhang; Susan W Sunnarborg; K Kirk McNaughton; Terrance G Johns; David C Lee; James E Faber
Journal:  Circ Res       Date:  2008-04-24       Impact factor: 17.367

Review 2.  Role of lectin-like oxidized low density lipoprotein-1 in fetoplacental vascular dysfunction in preeclampsia.

Authors:  Felipe A Zuniga; Valeska Ormazabal; Nicolas Gutierrez; Valeria Aguilera; Claudia Radojkovic; Carlos Veas; Carlos Escudero; Liliana Lamperti; Claudio Aguayo
Journal:  Biomed Res Int       Date:  2014-07-06       Impact factor: 3.411

3.  The Superantigen Toxic Shock Syndrome Toxin 1 Alters Human Aortic Endothelial Cell Function.

Authors:  Katarina Kulhankova; Kyle J Kinney; Jessica M Stach; Françoise A Gourronc; Isabella M Grumbach; Aloysius J Klingelhutz; Wilmara Salgado-Pabón
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

4.  High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis.

Authors:  Hua Jiang; Wenwei Liu; Yongshen Liu; Fengsheng Cao
Journal:  Anatol J Cardiol       Date:  2015-03-05       Impact factor: 1.596

Review 5.  An evolving new paradigm: endothelial cells--conditional innate immune cells.

Authors:  Jietang Mai; Anthony Virtue; Jerry Shen; Hong Wang; Xiao-Feng Yang
Journal:  J Hematol Oncol       Date:  2013-08-22       Impact factor: 17.388

6.  Cryptotanshinone inhibits TNF-α-induced LOX-1 expression by suppressing reactive oxygen species (ROS) formation in endothelial cells.

Authors:  Xiaoli Ran; Wenwen Zhao; Wenping Li; Jingshan Shi; Xiuping Chen
Journal:  Korean J Physiol Pharmacol       Date:  2016-06-23       Impact factor: 2.016

7.  Associations of myeloperoxidase, interleukin-17A and heparin-binding EGF-like growth factor levels with in-stent restenosis after percutaneous coronary intervention: a single-centre case-control study in China.

Authors:  Hua Jiang; Hongmei Zhang; Ying Yang; Xuezhou Yang
Journal:  BMJ Open       Date:  2020-11-06       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.